11/18
01:00 am
ipsey
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
Neutral
Report
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
11/15
11:00 am
ipsey
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Neutral
Report
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
10/23
01:00 am
ipsey
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
Low
Report
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance
9/23
07:13 am
ipsey
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Low
Report
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
9/20
08:57 am
ipsey
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
Low
Report
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
9/20
05:55 am
ipsey
Ipsen S.A. (OTCMKTS: IPSEY) was upgraded by analysts at Royal Bank of Canada from a "hold" rating to a "moderate buy" rating.
Low
Report
Ipsen S.A. (OTCMKTS: IPSEY) was upgraded by analysts at Royal Bank of Canada from a "hold" rating to a "moderate buy" rating.
9/16
08:45 am
ipsey
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Low
Report
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
9/15
08:45 am
ipsey
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Low
Report
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis